Covidien Announces First Patient Enrollment in DEFINITIVE AR Study

Covidien COV today announced the start of patient enrollment in the ev3 DEFINITIVE™ AR (Anti-Restenosis) study Imelda Hospital in Belgium with Dr. Patrick Peeters. DEFINITIVE AR is a European pilot study designed to address the challenge of restenosis (narrowing of a blood vessel) in patients with Peripheral Arterial Disease. The study will look at the effects of treating a diseased vessel with plaque excision prior to the use of a drug-coated balloon.